{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:10:42Z","timestamp":1769040642490,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.amepre.2021.05.017","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T17:30:34Z","timestamp":1628011834000},"page":"716-723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Hepatitis C Treatment Among Commercially or Medicaid-Insured Individuals, 2014\u20132018"],"prefix":"10.1016","volume":"61","author":[{"given":"Aaron M.","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ademola","family":"Osinubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noele P.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.amepre.2021.05.017_bib0001","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"issue":"14","key":"10.1016\/j.amepre.2021.05.017_bib0002","doi-asserted-by":"crossref","first-page":"399","DOI":"10.15585\/mmwr.mm6914a2","article-title":"Vital signs: newly reported acute and chronic hepatitis C cases - United States, 2009-2018","volume":"69","author":"Ryerson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.amepre.2021.05.017_bib0003","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010","volume":"160","author":"Denniston","year":"2014","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.amepre.2021.05.017_bib0004","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/cid\/ciw111","article-title":"Rising mortality associated with hepatitis C virus in the United States, 2003-2013","volume":"62","author":"Ly","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amepre.2021.05.017_bib0005","unstructured":"American Association for the Study of Liver Disease, Infectious Disease Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org Updated May 26, 2021. Accessed October 28, 2020."},{"key":"10.1016\/j.amepre.2021.05.017_bib0006","series-title":"Combating hepatitis B and C to reach elimination by 2030","year":"2016"},{"issue":"2","key":"10.1016\/j.amepre.2021.05.017_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC recommendations for hepatitis C screening among adults - United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR Recomm Rep"},{"issue":"12","key":"10.1016\/j.amepre.2021.05.017_bib0008","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/cid\/ciz714","article-title":"The consensus hepatitis C cascade of care: standardized reporting to monitor progress toward elimination","volume":"69","author":"Safreed-Harmon","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amepre.2021.05.017_bib0009","unstructured":"MarketScan research databases. IBM. https:\/\/www.ibm.com\/products\/marketscan-research-databases\/databases. Accessed April 29, 2021."},{"issue":"5","key":"10.1016\/j.amepre.2021.05.017_bib0010","first-page":"232","article-title":"Monitoring the hepatitis C care cascade using administrative claims data","volume":"24","author":"Isenhour","year":"2018","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.amepre.2021.05.017_bib0011","series-title":"A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report","year":"2017"},{"issue":"3","key":"10.1016\/j.amepre.2021.05.017_bib0012","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2007.03572.x","article-title":"The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases","volume":"27","author":"Kramer","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.amepre.2021.05.017_bib0013","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/pds.3721","article-title":"Coding algorithms for identifying patients with cirrhosis and hepatitis B or C virus using administrative data","volume":"24","author":"Niu","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.amepre.2021.05.017_bib0014","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2105\/AJPH.2015.302927","article-title":"Cascade of care for hepatitis C virus infection within the U.S. Veterans Health Administration","volume":"106","author":"Maier","year":"2016","journal-title":"Am J Public Health"},{"issue":"20","key":"10.1016\/j.amepre.2021.05.017_bib0015","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMp1302973","article-title":"Hepatitis C in the United States","volume":"368","author":"Holmberg","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amepre.2021.05.017_bib0016","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jvh.13199","article-title":"Defining the hepatitis C cure cascade in an urban health system using the electronic health record [published correction appears in J Viral Hepat. 2021;28(2):449]","volume":"27","author":"Miller","year":"2020","journal-title":"J Viral Hepat"},{"issue":"suppl 2","key":"10.1016\/j.amepre.2021.05.017_bib0017","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/00333549161310S213","article-title":"High-yield birth-cohort hepatitis C virus screening and linkage to care among underserved African Americans, Atlanta, Georgia, 2012-2013","volume":"131","author":"Miller","year":"2016","journal-title":"Public Health Rep"},{"key":"10.1016\/j.amepre.2021.05.017_bib0018","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugpo.2017.07.002","article-title":"Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review","volume":"47","author":"Bajis","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"suppl 2","key":"10.1016\/j.amepre.2021.05.017_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/00333549161310S201","article-title":"Strategies for expanding access to HBV and HCV testing and care in the United States: the CDC Hepatitis Testing and Linkage to Care Initiative, 2012-2014","volume":"131","author":"Ward","year":"2016","journal-title":"Public Health Rep"},{"key":"10.1016\/j.amepre.2021.05.017_bib0020","unstructured":"Viral Hepatitis: funded Partners and programs. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/hepatitis\/policy\/fundedpartners.htm. Accessed November 5, 2020."},{"issue":"2","key":"10.1016\/j.amepre.2021.05.017_bib0021","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/apc.2015.0222","article-title":"Treating hepatitis C in a Ryan White-funded HIV clinic: has the treatment uptake improved in the interferon-free directly active antiviral era?","volume":"30","author":"Cope","year":"2016","journal-title":"AIDS Patient Care STDs"},{"issue":"7","key":"10.1016\/j.amepre.2021.05.017_bib0022","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cgh.2016.03.040","article-title":"Disparities in absolute denial of modern hepatitis C therapy by type of insurance","volume":"14","author":"Lo Re","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.amepre.2021.05.017_bib0023","doi-asserted-by":"crossref","first-page":"226","DOI":"10.7326\/M15-0320","article-title":"Limited access to new hepatitis C virus treatment under state Medicaid programs","volume":"163","author":"Canary","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amepre.2021.05.017_bib0024","series-title":"Hepatitis C: the state of Medicaid access: 2017 national summary report","year":"2017"},{"issue":"3","key":"10.1016\/j.amepre.2021.05.017_bib0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of Sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann Intern Med"},{"issue":"18","key":"10.1016\/j.amepre.2021.05.017_bib0026","doi-asserted-by":"crossref","first-page":"465","DOI":"10.15585\/mmwr.mm6618a2","article-title":"State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs - United States, 2015-2016 [published correction appears in MMWR Morb Mortal Wkly Rep. 2017;66(29):795]","volume":"66","author":"Campbell","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379721003482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379721003482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:00:17Z","timestamp":1760083217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379721003482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0749379721003482"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2021.05.017","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C Treatment Among Commercially or Medicaid-Insured Individuals, 2014\u20132018","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2021.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine.","name":"copyright","label":"Copyright"}]}}